This article is more than 5 years old. Information may no longer be current.

Visudyne sales decreased from last year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — Global sales of verteporfin decreased 39.3% in the third quarter of 2006 compared to the same quarter of the previous year.

For the third quarter 2006, global sales of Visudyne (verteporfin for injection) were $75.1 million, representing a 21.2% decline compared to the second quarter of 2006, according to a press release from QLT.

"The decline in Visudyne sales has been more rapid than anticipated, and as a result we are lowering our 2006 annual Visudyne sales range from the previous range of $370 million to $385 million, to a new range of $340 million to $355 million," said Bob Butchofsky, the company's president and chief executive officer.

QLT co-promotes Visudyne with Novartis.